CTNNB1 and cancer: These therapies have largely proven most effective in ligand-dependent pre-clinical models but have shown limited efficacy in ligand-independent cancer models, typically due to constitutively active WNT signalling arising from mutations in WNT pathway components that operate downstream of Frizzled receptors, such as in CTNNB1 and APC.